目的 探究采用铝碳酸镁咀嚼片联合雷尼替丁治疗胃食管反流病的临床效果。方法 选取赤峰学院附属医院2016年7月—2017年7月收治的胃食管反流患者111例，随机分为对照组（55例）和治疗组（56例）。对照组患者口服盐酸雷尼替丁胶囊，1粒/次，2次/d；治疗组在对照组基础上嚼服铝碳酸镁咀嚼片，2片/次，3次/d。两组患者均经过4周治疗。观察两组患者临床疗效，比较治疗前后两组患者症状积分、生活质量评分和食管pH值。结果 治疗后，对照组临床有效率为81.82%，显著低于治疗组的96.43%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者症状积分明显降低，QOL评分明显升高，同组比较差异具有统计学意义（P<0.05）；同时治疗组患者的症状积分和QOL评分均显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者食管第一、二通道pH<4所占全部时间的百分比均显著下降，同组比较差异具有统计学意义（P<0.05）；且治疗组患者上述百分比明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 铝碳酸镁联合雷尼替丁治疗胃食管反流临床效果明显，能有效改善患者的病情和生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Hydrotalcite Chewable Tablets combined with ranitidine in treatment of gastroesophageal reflux disease. Methods Patients (111 cases) with gastroesophageal reflux disease in Affiliated Hospital of Chifeng University from July 2016 to July 2017 were randomly divided into control (55 cases) and treatment (56 cases). Patients in the control group were po administered with Ranitidine Hydrochloride Capsules, 1 grain/time, twice daily. Patients in the treatment group were chewing administered with Hydrotalcite Chewable Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the symptom scores, quality of life scores and the time proportion of esophageal pH < 4 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.82%, which was significantly lower than 96.43% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the symptom scores in two groups were significantly decreased, but the QOL scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these scores in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the percentage of the total time of pH < 4 in the first and second channel of esophagus in two groups was significantly decreased, and there were differences in the same group (P < 0.05). And the percentage of the total time in the treatment group after treatment were significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Hydrotalcite Chewable Tablets combined with ranitidine can effectively improve the symptom and quality of life in treatment of gastroesophageal reflux disease with significant effect, which has a certain clinical application value.